Document Basket

Saved pages

Saved documents

Please note: This information is saved in a cookie. In case your browser deletes cookies after a session, the information will be lost.

DKSH partners with AFT Pharmaceuticals to offer the first combination drug in Hong Kong December 20, 2018


			
				DKSH partners with AFT Pharmaceuticals to offer the first combination drug in Hong Kong

DKSH, the leading Market Expansion Services provider with a focus on Asia, and AFT Pharmaceuticals Limited, an Australasian pharmaceutical company, have partnered to introduce the first combination drug of paracetamol and ibuprofen called Maxigesic in Hong Kong.

Media release

DKSH partners with AFT Pharmaceuticals to offer the first combination drug in Hong Kong

DKSH, the leading Market Expansion Services provider with a focus on Asia, and AFT Pharmaceuticals Limited, an Australasian pharmaceutical company, have partnered to introduce the first combination drug of paracetamol and ibuprofen called Maxigesic in Hong Kong.

Hong Kong, December 20, 2018 – DKSH Hong Kong, the leading Market Expansion Services provider for companies seeking to grow their business, has started its partnership with AFT Pharmaceuticals Limited. The Australasian pharmaceutical company develops, licenses and sells a range of medical products globally. DKSH will bring its unique combination drug Maxigesic to patients in Hong Kong and Macau by providing full agency services, which include product registration, marketing and sales as well as distribution and logistics in both Hong Kong and Macau.

 

Maxigesic is the first combination drug of paracetamol and ibuprofen in the local markets. It provides double-action pain relief without codeine. DKSH targets to bring this product to market through local healthcare professionals with distribution points at hospitals, clinics and pharmacies. DKSH has been working steadfastly with AFT Pharmaceuticals to register Maxigesic in Hong Kong. The product registration is completed, with sales starting now.

 

“We are delighted to work with AFT Pharmaceuticals and support them in bringing the first combination drug to Hong Kong and Macau,” commented Grace Lau, Head, Management, Hong Kong, DKSH Hong Kong. “This kind of innovative medicine allows patients to achieve better and faster pain relief. We are thrilled to work with another multinational pharmaceutical company that brings real innovation to patients’ lives.”

 

“We are impressed by the in-depth market knowledge and extensive distribution network of DKSH. They supported us with the product registration and we are convinced that they will provide the same professionalism in sales promotion and local distribution,” said Dr. Hartley Atkinson, CEO and Founder of AFT Pharmaceuticals Limited. “We are looking forward to partnering with DKSH to further innovate the analgesic sector in Hong Kong and Macau.”